The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.

The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

The company also announced it would be divesting its Exosome Diagnostics business and selling it to MDxHealth.

The firm anticipates lower-than-previously-expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.

The test simultaneously detects and differentiates between SARS-CoV-2, influenza A/B, and respiratory syncytial virus.

At ADLM, the company provided a preview of its Liaison Nes point-of-care PCR instrument that is complementary to the firm's Liaison Plex syndromic testing system.

Including its COVID-19-related business, the company's second quarter revenues were down 43 percent year over year.